Reacting to the CATT Study: Will Makena Make a Difference?
This article was originally published in RPM Report
The long awaited head-to-head trial of Avastin vs. Lucentis in macular degeneration has finally reported results. It pits a $1,500 a dose therapy against a $50, unapproved alternative that most providers think is just as good. We just had that debate over Makena. Recent comments by FDA’s top drug review official suggest there may be another connection.
You may also be interested in...
The Makena controversy is moving to court, and likely to a very unhappy ending for KV Pharma. But FDA’s decidedly unusual communications about compounding in the midst of that controversy may have longer term implications.
On July 21, Roche reported strong first half sales of Lucentis. It was all downhill from there.
The new FDA senior leadership duo of Hamburg and Sharfstein are sending signs that they are ready to find some object lessons for high-visibility enforcement actions. A former FDA chief counsel and Just Department chief of staff warn that the agency should pict its targets carefully. Enforcing regulatory priorities instead of regulatory law can get the agency into difficult situations.